• Roche’s SMA drug gets PRIME regulatory status in Europe pharmaphorum
    December 19, 2018
    Roche is hoping to challenge Biogen with a new treatment for the rare muscle wasting disease spinal muscular atrophy – and the plans just got a boost after European regulators gave it special priority.
PharmaSources Customer Service